Generation of antibody-based therapeutics targeting the idiotype of B-cell malignancies
Abstract
A feature of many B-cell tumors is a surface-expressed immunoglobulin (sIg). The complementarity-determining regions (CDRs) of the sIg, termed the ‘idiotype’, are unique to each tumor. We report on a phage selection strategy to generate anti-idiotype therapeutics that reacts with sIg CDR3 sequences; the MEC1 B-cell tumor line was used as proof of concept.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 27, 2018
- Source ID
- 10.1093/abt/tby012
Entities
People
- Antonella Antignani
- David Fitzgerald
- Emily Weiss
- Evan Angelus
- Evgeny Arons
- Mitchell Ho
- Robert Kreitman
- Robert Sarnovsky
Organizations
- Laboratory of Molecular Biology
- National Cancer Institute
- United States Department of Defense